Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Horizon Discovery nets £37.8mm in AIM IPO

Executive Summary

In the largest IPO by a UK life sciences company to date, Horizon Discovery Ltd. (research tools for translational genomics and personalized medicine) netted £37.8mm ($62.3mm) through the sale of 22mm new shares priced at £1.80 apiece on London’s AIM, well above the company's original target of £25mm in its February announcement. Selling shareholders (including the University of Cambridge) brought in an additional £28.6mm.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies